Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5153222 | UNITED THERAP | Method of treating pulmonary hypertension with benzidine prostaglandins |
Oct, 2014
(9 years ago) | |
US6765117 | UNITED THERAP | Process for stereoselective synthesis of prostacyclin derivatives |
Oct, 2017
(6 years ago) | |
US9199908 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(4 days from now) | |
US10695308 | UNITED THERAP | Inhalation formulations of treprostinil |
Dec, 2024
(6 months from now) | |
US10076505 | UNITED THERAP | Inhalation formulations of Treprostinil |
Dec, 2024
(6 months from now) | |
US9713599 | UNITED THERAP | Parenteral formulations of treprostinil |
Dec, 2024
(6 months from now) | |
US8658694 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(4 years from now) | |
US8653137 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Sep, 2028
(4 years from now) | |
US7999007 | UNITED THERAP | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
Mar, 2029
(4 years from now) |
Remodulin is owned by United Therap.
Remodulin contains Treprostinil.
Remodulin has a total of 13 drug patents out of which 2 drug patents have expired.
Expired drug patents of Remodulin are:
Remodulin was authorised for market use on 28 September, 2023.
Remodulin is available in solution;intravenous, subcutaneous, injectable;iv (infusion), subcutaneous dosage forms.
Remodulin can be used as administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration, a method of treating pulmonary hypertension comprising parenterally administering a formulation comprising a) 0.1 to 5% w/v of treprostinil or a pharmaceutically acceptable salt thereof and b) a citrate buffer, treatment of pulmonary hypertension with ut-15, administration of remodulin diluted for intravenous infusion with sterile diluent for flolan or sterile diluent for epoprostenol sodium prior to administration, a method of treating a human patient suffering from pulmonary hypertension.
The generics of Remodulin are possible to be released after 29 March, 2029.
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 28 September, 2023
Treatment: Treatment of pulmonary hypertension with ut-15; Administration of remodulin diluted for intravenous infusion with sterile water for injection or 0.9% sodium chloride injection prior to administration...
Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS; SOLUTION;INTRAVENOUS, SUBCUTANEOUS